Management

Management in Novozymes A/S is headed by Novozymes' Board of Directors and the Executive Leadership Team. Our ten-member Board of Directors and seven-member Executive Leadership Team comprise broad and global management experience, comprehensive biotech expertise and in-depth knowledge of Novozymes' business. The members' competencies combine to ensure the best possible management of the company.  
 

Jørgen Buhl Rasmussen

Born 1955. Chairman of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Audit Committee and chairman of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for one year at a time.

Board positions

Chairman: F. Uhrenholt A/S
Member: Smurfit Kappa Group, Advisory Board of Blazar Capital

Special competencies

International business and management expertise, specifically within sales, marketing, branding, acquisitions, and financial and accounting expertise.

Cees de Jong

Born 1961. Vice Chairman of the Board. Member of the Audit Committee and the Nomination and Remuneration Committee. Member of the Board since 2020. Elected for one year at a time.

Board positions

Chairman: Chairman of Mediq B.V., ForFarmers N.V. and A-Mansia Biotech.

Special competencies

Extensive international business and management experience from the food, food ingredient and industrial biotech industries. 

Heine Dalsgaard

Born 1971. CFO, Carlsberg A/S. Chairman of the Audit Committee. Member of the Board since 2020. Elected for one year at a time.

Board positions

Chairman: Carlsberg Ejendomme Holding A/S and Carlsberg Global Business Services A/S

Member: Carlsberg Breweries A/S, Carlsberg Byen Komplementar ApS and Carlsberg Byen P/S.

Special competencies

Strong financial background and accounting expertise, as well as extensive experience in driving strategic results.

 

Sharon James

Born 1961. Former Senior Vice President, Global R&D, Bayer Consumer Health. Member of the Board since 2020. Elected for one year at a time.

Board positions

Member: Mölnlycke Health Care.

Special competencies

Broad international experience in commercial research and innovation pipeline management. 

Kasim Kutay

Born 1965. CEO, Novo Holdings A/S. Member of the Nomination and Remuneration Committee. Member of the Board since 2017. Elected for one year at a time.

Board positions

Member: Novo Nordisk A/S, ConvaTec Plc

Special competencies

Broad experience within biotechnology, mergers and acquisitions, and financial and accounting expertise.

 

This board member is not regarded as independent in the sense of the definition in the Danish Recommendations on Corporate Governance that apply to Danish listed companies.

Kim Stratton

Born 1962. Head of International Commercial, Shire International GmbH. Member of the Nomination and Remuneration Committee. Member of the Board since 2017. Elected for one year at a time.

Board positions

Member: European Federation of Pharmaceutical Industries and Associations (EFPIA)

Special competencies

Broad international commercial experience within sales and marketing, emerging markets, innovation pipeline management and sustainability.


 

Mathias Uhlén

Born 1954. Professor at the Royal Institute of Technology (Sweden) and the Technical University of Denmark (DTU). Member of the Board since 2007. Elected for one year at a time.

Board positions

Chairman: Atlas Antibodies AB, Antibodypedia AB, ScandiBio Therapeutics AB
Vice Chairman: Affibody Medical AB
Member: Bure Equity AB (publ. Sweden)

Special competencies

Broad experience in research and biotechnology.

Lena Bech Holskov

Born 1967. Employee representative.

Safety Adviser. Member of the Board since 2013. Elected for four years at a time.

Anders Hentze Knudsen

Born 1959. Employee representative.

Senior Operator. Employee representative. Member of the Board since 2013. Elected for four years at a time.

Lars Bo Køppler

Born 1962. Employee representative.

Technician. Member of the Board since 2010. Elected for four years at a time.

Ester Baiget

President and CEO

Ester is an experienced international leader with a strong track-record.

Ester came to Novozymes after working as president for Dow’s Industrial Solutions business unit and a member of the executive leadership team. She joined Dow in 1995 as an engineer in Tarragona, Spain. In her years as Business President for Industrial Solutions, the business expanded the market, improved its market-leading position, delivered double-digit growth and strong earnings. 

She holds a chemical engineering degree and an MBA from the University of Tarragona (Spain).

Lars Green

Executive Vice President and CFO

Lars Green, born 1967, is responsible for the Finance, IT & legal functions.

Lars worked for Novo Nordisk A/S for 27 years where he headed up Business Services and Compliance, and – as EVP – was part of Novo Nordisk’s Executive Management team. Before assuming his current position, he was head of Finance & Operations for Novo Nordisk in North America. He was a member of Novozymes’ Board of Directors from 2014 and chairman of the Audit Committee until his appointment as EVP and CFO.

He has in-depth knowledge of the Novo Group’s business, international experience from managing global biotechnology and biopharma companies, and financial and accounting expertise.

Lars holds an M.Sc. in Business Administration from Aarhus University, Denmark.

 

Tina Sejersgård Fanø

Executive Vice President, Agriculture & Industrial Biosolutions

Tina Sejersgård Fanø, born 1969, is responsible for application research, technical service, sales and marketing in the Agriculture & Bioenergy division. 

Tina has been with Novozymes since she graduated as a chemical engineer from the Technical University of Denmark in 1993. She started as a trainee and worked her way up through the organization holding a number of positions in applied research, marketing and business development. 

From 2013-2016 she was Vice President of Business Operations, Europe, Middle East and Africa. Tina has significant experience in developing and managing global partnerships and has been instrumental in negotiating several major business deals for Novozymes over the years.  

She currently serves as member of the board of DLF Seeds & Science and PPS A/S. 

Claus Crone Fuglsang

CSO and Executive Vice President, Research & Development

Claus Crone Fuglsang is CSO and Executive Vice President of Research & Development at Novozymes, responsible for Enzyme Research, Microbe Research, Product & Process Development, Regulatory Affairs and Product Safety, Intellectual Property & Licensing and R&D Portfolio & Projects. The Research & Development function is the foundation for finding biological solutions for better lives.

Since joining Novozymes in 1993, Claus has been in several leadership roles in R&D in both Denmark and the US. Prior to his current position, he spent over four years as one of only two Senior Vice Presidents in the company, responsible for driving Novozymes’ core research and technology development.

Claus has a Master’s degree in Biochemistry from the University of Copenhagen and an MBA from Heriot-Watt University, Edinburgh Business School.

Anders Lund

Executive Vice President, Consumer Biosolutions

Anders Lund, born 1973, is responsible for application research, technical service, sales and marketing in the Household Care & Technical Industries division. 

Anders has been with Novozymes since he graduated from Aarhus University, Denmark in 1999. In a career spanning several leadership positions, he has been in charge of Household Care Marketing, Supply Chain Management and Global Marketing. Most recently, he was Vice President of Business Operations, North and South America.

Anders has a strong commercial and strategic background and has been a significant part of shaping Novozymes’ strategies over the last 10 years. He also brings strong customer relationships, especially in the Household Care and Biofuel areas.

 

Graziela Chaluppe dos Santos Malucelli

Executive Vice President, Operations, Supply & Quality

Graziela Chaluppe dos Santos Malucelli is Executive Vice President of Operations, Supply & Quality at Novozymes, responsible for Operations, Supply Chain, Global Planning & Optimization, Engineering & Sourcing Facilities and Quality, Environment & Safety. 

Since joining Novozymes in 1998, Graziela has developed diverse key functions within the organization and been based out of Brazil, Denmark and China. Prior to her current role, she spent over four years as one of only two Senior Vice Presidents in the company, with oversight of Supply Operations.

Graziela is trained as an engineer and holds a master’s degree in food engineering.

Thomas Videbæk

Executive Vice President, Strategy & Business Transformation; People, Sustainability & Brand

Previously, he developed diverse key functions within the organization, spanning both the commercial and operational side of the business. He was Vice President of Sales & Customer Solutions from 2005 to 2007 and served as Vice President for Supply Chain Operations from 2003 to 2005, where he helped build a global organization for Novozymes’ supply chain.

From 1998 to 2003, Thomas served as both Vice President for Cereal Food and Beverage Marketing and General Manager for Novozymes Switzerland. 

Prior to joining Novozymes, Thomas worked for Novo Nordisk A/S, with roles including Director for Strategic Marketing, Food and Feed enzymes, where he set strategy for the food and feed industries. He also worked in a leadership position within the starch and textile businesses, the latter in the company’s U.S. operations. 

Thomas holds a Ph.D. and an M.Sc. In Chemical Engineering from the Technical University of Denmark (DTU), as well as a B.Com. in International Business from Copenhagen Business School.

He currently serves as member of the board of Evolva SA, and he is Vice Chairman of the Board of Albumedix A/S. 

Ownership

Novozymes’ common stock consists of A shares and B shares, both with a nominal value of DKK 2 per share. A shares carry 20 votes each whilst B shares carry 2 vote each. At the end of 2019, Novozymes had more than 52,000 shareholders, of whom 95% were private shareholders in Denmark. Novozymes held 4.1% of the B shares, equivalent to 3.3% of the total common stock. Roughly 70% of the B shares were held outside Denmark. Fifty institutional investors, including Novo Holdings A/S, owned approximately 50% of the B shares. Novo Holdings A/S held 25.5% of the total common stock in Novozymes and controlled 72.0% of the votes. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, an independent Danish foundation whose objective is to provide a stable base for the companies within the Novo Group and to support scientific and humanitarian purposes.

 

 

 

Subsidiaries in Novozymes

Find a list of the names of Novozymes' subsidiaries listed according to the countries they are placed in.